Literature DB >> 3115205

Regression of atherosclerosis by the intravenous infusion of specific biochemical nutrient substrates in animals and humans.

S J Dudrick.   

Abstract

Preliminary studies in 400 New Zealand albino rabbits produced a reliable animal model of nutrient-induced atherosclerosis that simulated that observed in humans. Atherosclerosis was then induced in an additional 1600 rabbits in sets of 40 animals each, maintaining plasma cholesterol concentrations between 1000 and 2000 mg/dL for 6-20 weeks. In each set, 10 control rabbits were killed to document baseline atherosclerosis, and the other 30 rabbits were assigned randomly to one of three groups of 10 rabbits. Groups of 10 rabbits were either continued on the atherogenic diet (group I), given standard laboratory rabbit pellets (group II), or infused continuously with specially formulated anticholesterol solutions via central venous catheters (group III) for 6 weeks. At autopsy, atherosclerotic lesions consistently involved 85-95% of the aorta in group I. In group II, atherosclerosis was comparable with the baseline control group with no regression. In group III, regression of atherosclerosis by 90-95% was consistently documented. Correlations between plasma amino acids and plasma cholesterol concentrations were established in four humans with severe atherosclerosis to maximize the cholesterol reduction capacity of the amino acid formulation. Infusion of the modified total parenteral nutrition solution induced prompt reduction in plasma cholesterol levels by 40-60% regardless of the initial level and was accompanied by evidence of regression of atherosclerosis after a 90-day infusion therapy period.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3115205      PMCID: PMC1493195          DOI: 10.1097/00000658-198709000-00008

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  7 in total

1.  Total parenteral nutrition in familial hypercholesterolemia: importance of caloric control.

Authors:  H Yamashita; A Okada; T Itakura; K Nakao; Y Kawashima; A Yamamoto
Journal:  Surgery       Date:  1986-03       Impact factor: 3.982

2.  Portacaval shunt in hyperlipoproteinaemia.

Authors:  T E Starzl; C W Putnam; H P Chase; K A Porter
Journal:  Lancet       Date:  1973-10-27       Impact factor: 79.321

3.  Portal diversion for the treatment of glycogen storage disease in humans.

Authors:  T E Starzl; C W Putnam; K A Porter; C G Halgrimson; J Corman; B I Brown; R W Gotlin; D O Rodgerson; H L Greene
Journal:  Ann Surg       Date:  1973-10       Impact factor: 12.969

Review 4.  The pathogenesis of atherosclerosis--an update.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

Review 5.  Quantification of coronary artery stenosis in vivo.

Authors:  K L Gould
Journal:  Circ Res       Date:  1985-09       Impact factor: 17.367

6.  Portacaval shunt for glycogen storage disease: value of prolonged intravenous hyperalimentation before surgery.

Authors:  J Folkman; A Philippart; W J Tze; J Crigler
Journal:  Surgery       Date:  1972-08       Impact factor: 3.982

7.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

Authors:  J Stamler; D Wentworth; J D Neaton
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.